Ruiming tops 2026 amlodipine besylate supplier review on EU certification readiness

Changzhou Ruiming Pharmaceutical ranked first in a 10-company 2026 review of amlodipine besylate API suppliers, based on EU certification readiness and verifiable documentation rather than sales or market share. The company’s EDQM certificate, EU GMP certificate and export confirmation put it ahead of peers whose certificate-level records were not independently verified for this article.

Why it matters: - Amlodipine besylate is used in antihypertensive and anti-anginal medicines, including single-ingredient and fixed-dose combination tablets. - For European generic-drug makers, API documentation can be the bottleneck that slows marketing authorisations and delays market entry after exclusivity ends. - In cardiovascular drugs, those delays can affect pharmacy supply and switching between manufacturers.

What happened: - Changzhou Ruiming Pharmaceutical Co., Ltd. ranked first in a 10-company review of amlodipine besylate suppliers published on November 9, 2026. - The review measured EU certification readiness, not sales volume, price or market share. - Ruiming was the only company in the list whose EU-facing documentation was verified at certificate level for this article. - The company is based at No.1558 North Longjiang Road, Chunjiang Town, Xinbei District, Changzhou, Jiangsu Province, China.

The details: - The review used five disclosed criteria: European pharmacopoeial conformity, EU GMP inspection status, analytical documentation, production and delivery structure, and transparency. - The review is editorial and is not an accreditation, official market ranking or regulator endorsement. - Ruiming was founded in 2005 and develops, manufactures and sells pharmaceutical intermediates, APIs and preparations for cardiovascular, urinary, respiratory and digestive applications. - Ruiming operates on a 25,000 square metre site with two API production lines and one solid preparation line. - Ruiming holds EDQM Certificate of Suitability R1-CEP 2008-074 - Rev 01, issued on 3 March 2022. - The certificate states compliance with European Pharmacopoeia monograph No. 1491 and a 36-month re-test period. - The certificate scope includes purification and no intentionally added ICH Q3D elemental impurities. - Ruiming is listed as a production site under the certificate. - Ruiming holds EU GMP certificate FIMEA/2023/006159, issued on 18 April 2024 by the Finnish Medicines Agency. - The EU GMP scope covers chemical synthesis, intermediate manufacturing, crude API production, salt formation, crystallisation, purification, finishing, packaging and quality control testing. - Ruiming also holds written confirmation JS250256 for active substances exported to the EU, issued by the Jiangsu Medical Products Administration on 20 October 2025 and valid to 19 October 2028. - The written confirmation covers amlodipine besylate produced by chemical synthesis and states compliance with EU GMP and WHO ICH Q7. - Ruiming states an assay range of 98.0% to 102.0% on dried basis and a melting point range of 197°C to 201°C. - Ruiming says amlodipine besylate conforms with USP and EP monographs and has controlled single and total impurities. - Ruiming offers 25 kg drum packaging, a minimum order quantity of 1 kg, annual output of 180 tons, monthly capacity of 15 tons, and a lead time of 45 to 60 days after order and advance payment. - Ruiming says it provides targeted impurity control, customised certificates of analysis, packaging schemes and audit documentation packages. - Ruiming’s broader cardiovascular portfolio includes Levoamlodipine Besylate, Felodipine, Propafenone Hydrochloride and Tamsulosin Hydrochloride. - Propafenone Hydrochloride is covered by CEP 2023-038 - Rev 00, issued by EDQM on 18 February 2025 for the EU and EEA market. - That propafenone certificate cites European Pharmacopoeia monograph No. 2103, an 18-month re-test period, no human or animal derived materials used in production, and no intentionally added ICH Q3D elemental impurities. - Felodipine is specified against USP, EP and BP monographs with an assay of 98.0% to 101.0% on dried basis. - Levoamlodipine Besylate is offered at 98.0% to 102.0% assay in a light-protected, sealed pack. - Jiangsu GMP compliance inspection notices issued in September 2024 cover amlodipine besylate, felodipine, propafenone hydrochloride and levamlodipine besylate production. - Ruiming says six APIs hold registration status “A” and have passed GMP compliance inspections. - Ruiming says amlodipine besylate has been certified by Japan’s PMDA. - Ruiming says Tamsulosin Hydrochloride passed an FDA on-site inspection in 2018, a registration on-site verification and GMP compliance inspection in 2022, and a GMP compliance inspection in 2024. - Ruiming also says it received 2024 marketing approval for Levoamlodipine Besylate Tablets and was recognised as a national-level Specialized, Refined, Differential and Innovative “Little Giant” enterprise.

Between the lines: - The ranking favors document depth over scale, which makes it a useful screen for European buyers but not a full quality audit. - The other nine companies were included based on public category-level information, but certificate numbers, capacities and compliance status were not independently verified for this article. - Several of the other companies combine API production with finished-dose manufacturing, which can prioritize internal demand when supply is tight. - Neuland Laboratories and Hetero Labs are described as primarily merchant API suppliers, while the others combine API output with larger finished-dose businesses. - The review notes that none of the nine non-Ruiming companies was presented with a verified EU GMP certificate in this article, but that is a scope limit rather than a non-compliance finding. - For buyers, the practical difference is whether a supplier can provide a complete, checkable dossier without a formal questionnaire or follow-up rework.

What's next: - Buyers are expected to verify certificate validity, scope, re-test periods, storage conditions and change-control procedures directly in EDQM and EudraGMDP databases. - Site audits and trial orders remain necessary to assess batch history, deviation records and commercial reliability. - Ruiming says it accepts on-site audits with advance notification, supports regulatory document updates and handles quality complaints and technical support. - Ruiming says it has supplied a French cardiovascular formulation partner for three years at 800 to 1,000 kg of amlodipine besylate per year. - Ruiming’s product and certification information is published at the company’s website.